David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center

Articles by David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center

Metastatic Gastric Cancer: Recent Advances and Future Directions

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Perioperative Strategies in Metastatic Gastric Cancer

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Promising Later-Line Trials

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Promising Second-Line Trials

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Novel Agents Targeting FGF

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Gastric Cancer: Frontline Checkpoint Inhibitor Trials

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Promising Frontline Trials

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Emerging Biomarkers in Metastatic Gastric Cancer

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Later Lines of Therapy in Metastatic Gastric Cancer

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Chemotherapy + Ramucirumab as Second-Line Therapy in mGC

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Global Use of Second-Line Therapy in mGC

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Identifying Disease Progression

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Switch Maintenance in Gastric Cancer: Results of JAVELIN Gastric 100

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Gastric Cancer: Global Perspectives on Maintenance Therapy

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Is Frontline IO Therapy Appropriate in Gastric Cancer?

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Factors in Selecting Frontline Therapy

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Global Use of Frontline Therapy in Metastatic Gastric Cancer

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Latest Updated Articles

Global Use of Frontline Therapy in Metastatic Gastric Cancer
June 1st 2020
Perioperative Strategies in Metastatic Gastric Cancer
June 1st 2020
Is Frontline IO Therapy Appropriate in Gastric Cancer?
June 1st 2020
Metastatic Gastric Cancer: Identifying Disease Progression
June 1st 2020
Emerging Biomarkers in Metastatic Gastric Cancer
June 1st 2020
Switch Maintenance in Gastric Cancer: Results of JAVELIN Gastric 100
June 1st 2020

Trending on OncLive

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL

LITESPARK-012, XmAb819, and PE-PE Data Headline Key Kidney Cancer Findings From ESMO 2026